Bruker Corporation (Nasdaq: BRKR) announced today that it has entered into a definitive share purchase agreement with TecFin S.à r.l., a controlled af ...

ELITech offers the proprietary, fully automated sample-to-answer (S2A) systems InGenius® and BeGenius® for molecular testing in mid-sized hospitals Diversified ELITech MDx assay portfolio ...

ELITechGroup Molecular Diagnostics Receives FDA Clearance for its Real-Time PCR Assay for the Detection of Herpes Simplex Virus 1&2 and ELITe InGenius® Sample-to-Result Instrument ...

If you're hungry for more Samsung "Ingenius" ads, what's wrong with you? Regardless, two more are here, and they're perfectly cringe-worthy.

ELITech's breadth of testing menu, ease of use, and fast time-to-result complements Bruker's novel LiquidArray syndromic panels, specialty fungal infection, tuberculosis, mycobacteria and HIV MDx ...

ELITechGroup, known for its innovative molecular diagnostic (MDx) systems InGenius® and BeGenius®, has over 500 employees and holds more than 40 active patents.

Mirina, the new entity, gained Nanogen’s technology that aims to enhance miRNA drugs. Nanogen and The Elitech Group entered a definitive merger agreement. Separately, Nanogen also created a ...

Bruker Corporation announced today that it has entered into a definitive share purchase agreement with TecFin S. à r.l., a controlled affiliate of PAI Partners, a pre-eminent private equity firm ...

ELITech's breadth of testing menu, ease of use, and fast time-to-result complements Bruker's novel LiquidArray® syndromic panels, specialty fungal infection, tuberculosis, mycobacteria and HIV ...